Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD

ELITE PHARMACEUTICALS INC /NV/

Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.
Branded Vyvanse annual sales ~$4.3B (12 months ending Oct 2024, per IQVIA).
Product marketed under Elite Laboratories label; company operates cGMP/DEA facility in Northvale, NJ.
This generic version is indicated for treatment of attention deficit hyperactivity disorder (ADHD).
Launch represents expansion of Elite's niche generic product portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.